Patient no. | Sex | Age (yrs) | Tumor stage | Diagnosis (tumor type) | Localization of cervical lymph node metastases | PET result | Result of directed biopsy | Did PET result alter treatment strategy? |
---|---|---|---|---|---|---|---|---|
1 | M | 55 | N3 | PDC | II, III | negative | n/a | No |
2 | M | 57 | N1 | SCC | III | negative | n/a | No |
3 | M | 65 | N1 | SCC | II | negative | n/a | No |
4 | M | 65 | N2a | SCC | II | negative | n/a | No |
5 | F | 72 | N2a | UC | II | negative | n/a | No |
6 | M | 72 | N3 | SCC | V | pulmonary metastases | n/a | Yes |
7 | M | 50 | N1 | SCC | II | hypopharynx | SCC | Yes |
8 | M | 55 | N3 | SCC | II, III, V | negative | n/a | No |
9 | M | 40 | N1 | SCC | II | oropharynx; bone and hepatic metastases | SCC | Yes |
10 | M | 69 | N2b | UC | II,III | bone and hepatic metastases | n/a | Yes |
11 | M | 44 | N3 | SCC | II, III | negative | n/a | No |
12 | M | 48 | N2b | SCC | II | negative | n/a | No |
13 | M | 70 | N2a | SCC | II, III | negative | n/a | No |
14 | F | 57 | N1 | PDC | I | base of tongue | SCC | Yes |
15 | M | 48 | N2a | PDC | II | nasopharynx; bone and extracervical lymph node metastases | negative | Yes |
16 | M | 48 | N3 | Adenocarcinoma | II, III | negative | n/a | No |
17 | M | 54 | N3 | SCC | II, III | negative | n/a | No |
18 | M | 47 | N2c | SCC | III, IV | hypopharynx | negative | No |
19 | M | 57 | N2b | PDC | II, III, V | hepatic metastases | n/a | Yes |
20 | M | 68 | N2a | SCC | III | supraglottis | negative | No |
21 | M | 36 | N3 | Adenocarcinoma | II, III, IV, V | extracervical lymph node metastases | n/a | Yes |
22 | M | 68 | N3 | SCC | II, V | negative | n/a | No |
23 | M | 44 | N3 | SCC | II, III, IV, V | palatine tonsil | negative | No |
24 | M | 45 | N2a | PDC | II | extracervical lymph node metastases | n/a | Yes |
25 | F | 56 | N2b | Adenocarcinoma | V | bone and pulmonary metastases | n/a | Yes |
26 | M | 53 | N3 | PDC | II, III | bone metastases | n/a | Yes |
27 | M | 68 | N3 | SCC | II, III | lung (primary) | SCC | Yes |
28 | M | 47 | N2a | SCC | II | negative | n/a | No |
29 | M | 46 | N3 | SCC | II, V | negative | n/a | No |
30 | M | 75 | N2b | PDC | I, II, V | parotid gland | SCC | Yes |
31 | M | 55 | N3 | SCC | II, III | negative | n/a | No |
32 | M | 56 | N2b | PDC | II | negative | n/a | No |
33 | M | 61 | N2a | SCC | IV | negative | n/a | No |
34 | F | 51 | N3 | SCC | II | palatine tonsil | SCC | Yes |
35 | M | 48 | N1 | PDC | I | bone metastases | n/a | Yes |
36 | M | 61 | N3 | SCC | II, III | negative | n/a | No |
37 | M | 58 | N2b | SCC | II, III | nasopharynx | negative | No |
38 | F | 81 | N1 | SCC | IV | negative | n/a | No |
39 | M | 78 | N1 | SCC | V | sinonasal primary and extracervical lymph node metastases | SCC | Yes |
40 | M | 69 | N2a | PDC | II | hepatic metastases | n/a | Yes |
41 | M | 60 | N3 | SCC | II, III, IV | bone and extracervical lymph node metastases | n/a | No |
42 | M | 52 | N3 | PDC | II, V | pulmonary and hepatic metastases | n/a | Yes |
43 | M | 73 | N3 | SCC | II, V | negative | n/a | No |
44 | M | 56 | N3 | PDC | II, III | bone and extracervical lymph node metastases | n/a | No |
45 | M | 69 | N3 | SCC | IV, V | esophageal primary, bone and extracervical lymph node metastases | SCC | Yes |
46 | M | 45 | N2a | Adenocarcinoma | V | extracervical lymph node metastases | n/a | Yes |
47 | M | 60 | N2b | SCC | I, II | pulmonary, bone and extracervical lymph node metastases | n/a | No |
48 | M | 54 | N2b | SCC | I, II | base of tongue | SCC | Yes |
49 | M | 44 | N2b | UC | II, III, IV, V | negative | n/a | No |